Thrombospondin 2 inhibits metastasis of human malignant melanoma through microenvironment-modification in NOD/SCID/γc null (NOG) mice

International Journal of Oncology

Volumn 34, Issue 1, 2009, Pages 5-13

  Chijiwa, Tsuyoshi ^a,d   Abe, Yoshiyuki ^a   Ikoma, Norihiro ^a   Yamazaki, Hitoshi ^a   Tsukamoto, Hideo ^a   Suemizu, Hiroshi ^c   Kawai, Kenji ^c   Wakui, Masatoshi ^c   Nishime, Chiyoko ^c   Matsumoto, Hozumi ^a   Matsuyama, Masahiro ^a   Mukai, Masaya ^b   Ueyama, Yoshito ^a   Nakamura, Masato ^a,c  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^c CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^d JPN Self Defense Forces Hospital Yokosuka   (Japan)

Author keywords

Malignant melanoma; Metastasis; Microenvironment; Mouse model; Plasminogen activator; Thrombospondin 2

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; THROMBOSPONDIN 2; THROMBOSPONDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER METASTASIS; LIVER WEIGHT; MALE; MELANOMA; METASTASIS INHIBITION; MICROENVIRONMENT; MOLECULAR CLONING; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; SCID MOUSE; UPREGULATION; VASCULARIZATION; ZYMOGRAPHY; ANIMAL; CELL MOTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); NORTHERN BLOTTING; PHYSIOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOSPONDINS; TRANSFECTION;

EID: 60749135094     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000123     Document Type: Article

References (46)

1. Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF and Bouck N: Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 217: 326-332, 1995.
2. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P and Detmar M: Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96: 14888-14893, 1999.
3. Kyriakides TR, Zhu YH, Yang Z and Bornstein P: The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice. J Histochem Cytochem 46: 1007-1015, 1998.
4. Lawler J: The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 12: 634-640, 2000.
5. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
6. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ and Bouck N: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122: 497-511, 1993.
7. Adolph KW: Relative abundance of thrombospondin 2 and thrombospondin 3 mRNAs in human tissues. Biochem Biophys Res Commun 258: 792-796, 1999.
8. Oshika Y, Masuda K, Tokunaga T, Hatanaka H, Kamiya T, Abe Y, Ozeki Y, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y and Nakamura M: Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clin Cancer Res 4: 1785-1788, 1998.
9. Tokunaga T, Nakamura M, Oshika Y, Abe Y, Ozeki Y, Fukushima Y, Hatanaka H, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Tamaoki N and Ueyama Y: Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 79: 354-359, 1999.
10. Kazuno M, Tokunaga T, Oshika Y, Tanaka Y, Tsugane R, Kijima H, Yamazaki H, Ueyama Y and Nakamura M: Thrombospondin-2 (TSP2) expression is inversely correlated with vascularity in glioma. Eur J Cancer 35: 502-506, 1999.
11. Tomii Y, Kamochi J, Yamazaki H, Sawa N, Tokunaga T, Ohnishi Y, Kijima H, Ueyama Y, Tamaoki N and Nakamura M: Human thrombospondin 2 inhibits proliferation of microvascular endothelial cells. Int J Oncol 20: 339-342, 2002.
12. Kamochi J, Tokunaga T, Tomii Y, Abe Y, Hatanaka H, Kijima H, Yamazaki H, Watanabe N, Matsuzaki S, Ueyama Y and Nakamura M: Overexpression of the thrombospondin 2 (TSP2) gene modulated by the matrix metalloproteinase family expression and production in human colon carcinoma cell line. Oncol Rep 10: 881-884, 2003.
13. Andreasen PA, Egelund R and Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40, 2000.
14. Cornil I, Man S, Fernandez B and Kerbel RS: Enhanced tumorigenicity, melanogenesis, and metastases of a human malignant melanoma after subdermal implantation in nude mice. J Natl Cancer Inst 81: 938-944, 1989.
15. Taylor CW, Grogan TM, Lopez MH, Leong SP, Odeleye A, Feo-Zuppardi FJ and Hersh EM: Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency. Lab Invest 67: 130-137, 1992.
16. Ikoma N, Yamazaki H, Abe Y, Oida Y, Ohnishi Y, Suemizu H, Matsumoto H, Matsuyama T, Ohta Y, Ozawa A, Ueyama Y and Nakamura M: S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gamma(c)(null) (NOG) mouse model. Oncol Rep 14: 633-637, 2005.
17. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T and Nakahata T: NOD/SCID/ gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-3182, 2002.
18. Bein K and Simons M: Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275: 32167-32173, 2000.
19. Abe Y, Ohnishi Y, Yoshimura M, Ota E, Ozeki Y, Oshika Y, Tokunaga T, Yamazaki H, Ueyema Y, Ogata T, Tamaoki N and Nakamura M: P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. Br J Cancer 74: 1929-1934, 1996.
20. Nishi M, Abe Y, Tomii Y, Tsukamoto H, Kijima H, Yamazaki H, Ohnishi Y, Iwasaki M, Inoue H, Ueyama Y and Nakamura M: Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. Int J Oncol 26: 1517-1524, 2005.
21. Oida Y, Gopalan B, Miyahara R, Inoue S, Branch CD, Mhashilkar AM, Lin E, Bekele BN, Roth JA, Chada S and Ramesh R: Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther 4: 291-304, 2005.
22. Hanzawa M, Shindoh M, Higashino F, Yasuda M, Inoue N, Hida K, Ono M, Kohgo T, Nakamura M, Notani K, Fukuda H, Totsuka Y, Yoshida K and Fujinaga K: Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis 21: 1079-1085, 2000.
23. Ramont L, Pasco S, Hornebeck W, Maquart FX and Monboisse JC: Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system. Exp Cell Res 291: 1-10, 2003.
24. Miskin R and Abramovitz R: One-phase reverse zymography after denaturing gel electrophoresis: high sensitivity detection of activity of plasminogen activator inhibitor 2 and other protease inhibitors. Fibrinolysis 9: 331-342, 1995.
25. Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N and Nakamura M: Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gamma(c) (null) (NOG) mice. Int J Oncol 31: 741-751, 2007.
26. Hatanaka H, Oshika Y, Abe Y, Yoshida Y, Hashimoto T, Handa A, Kijima H, Yamazaki H, Inoue H, Ueyama Y and Nakamura M: Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angiogenesis inhibitor 1 (BAI1). Int J Mol Med 5: 181-183, 2000.
27. De Vries TJ, van Muijen GN and Ruiter DJ: The plasminogen activation system in melanoma cell lines and in melanocytic lesions. Melanoma Res 6: 79-88, 1996.
28. Neurath H: Evolution of proteolytic enzymes. Science 224: 350-357, 1984.
29. Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195, 1993.
30. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
31. De Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ and van Muijen GN: Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144: 70-81, 1994.
32. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S and Kwaan HC: Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96: 2593-2600, 1995.
33. Morita Y, Hayashi Y, Kanamaru T, Itoh T, Suzuki S, Yamamoto M, Kuroda Y and Itoh H: Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells. Jpn J Cancer Res 90: 747-752, 1999.
34. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
35. Eitzman DT, Krauss JC, Shen T, Cui J and Ginsburg D: Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87: 4718-4722, 1996.
36. Ma D, Gerard RD, Li XY, Alizadeh H and Niederkorn JY: Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 90: 2738-2746, 1997.
37. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC and Lawrence DA: Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276: 33964-33968, 2001.
38. Mueller BM, Yu YB and Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 92: 205-209, 1995.
39. Nakamura M, Oida Y, Abe Y, Yamazaki H, Mukai, M, Matsuyama M, Chijiwa T, Matsumoto H and Ueyama Y: Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells. Mol Med Rep 1: 423-427, 2008.
40. Yang Z, Kyriakides TR and Bornstein P: Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol Biol Cell 11: 3353-3364, 2000.
41. Albo D, Berger DH, Vogel J and Tuszynski GP: Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer. J Gastrointest Surg 3: 411-417, 1999.
42. Guo N, Krutzsch HC, Inman JK and Roberts DD: Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57: 1735-1742, 1997.
43. Armstrong LC, Bjorkblom B, Hankenson KD, Siadak AW, Stiles CE and Bornstein P: Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 13: 1893-1905, 2002.
44. Kim MS, Kim YK, Cho KH and Chung JH: Infrared exposure induces an angiogenic switch in human skin that is partially mediated by heat. Br J Dermatol 155: 1131-1138, 2006.
45. Werb Z, Vu TH, Rinkenberger JL and Coussens LM: Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 107: 11-18, 1999.
46. Kyriakides TR, Zhu YH, Yang Z, Huynh G and Bornstein P: Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 159: 1255-1262, 2001.